Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bristol Increases Wholesaler Inventory Liability Legal Reserves By $300 Mil.

Executive Summary

Bristol-Myers Squibb plans to increase its legal reserves relating to wholesaler inventory issues by $300 mil., the second increase in three months

You may also be interested in...



Bristol settles inventory class action

Bristol-Myers Squibb has $170 mil. left in its legal reserve for wholesaler inventory litigation after paying $300 mil. to settle a securities class action lawsuit. The settlement is related to inventory accounting and Bristol's investment in ImClone's Erbitux. Bristol increased its legal reserves for wholesaler inventory litigation by $320 mil. to $470 mil. in the second quarter. The $320 mil. reserve was the majority of a $455 mil. second quarter charge for litigation-related expenses. Bristol expected the charge would total $400 mil. (1"The Pink Sheet" July 5, 2004, p. 28)...

Bristol settles inventory class action

Bristol-Myers Squibb has $170 mil. left in its legal reserve for wholesaler inventory litigation after paying $300 mil. to settle a securities class action lawsuit. The settlement is related to inventory accounting and Bristol's investment in ImClone's Erbitux. Bristol increased its legal reserves for wholesaler inventory litigation by $320 mil. to $470 mil. in the second quarter. The $320 mil. reserve was the majority of a $455 mil. second quarter charge for litigation-related expenses. Bristol expected the charge would total $400 mil. (1"The Pink Sheet" July 5, 2004, p. 28)...

Bristol Pulls Serzone; Cites Generic Erosion, Not Safety Issues

In a letter to wholesalers, Bristol said the antidepressant will no longer be shipped after June 14. Public Citizen called the withdrawal inadequate since the company is not ordering a recall and nefazodone generics are still available.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS044271

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel